Head-To-Head Survey: Soleno Therapeutics (NASDAQ:SLNO) vs. Hyperfine (NASDAQ:HYPR)

Soleno Therapeutics (NASDAQ:SLNOGet Rating) and Hyperfine (NASDAQ:HYPRGet Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends and risk.

Volatility and Risk

Soleno Therapeutics has a beta of 0.42, indicating that its share price is 58% less volatile than the S&P 500. Comparatively, Hyperfine has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500.

Insider and Institutional Ownership

69.5% of Soleno Therapeutics shares are owned by institutional investors. Comparatively, 22.7% of Hyperfine shares are owned by institutional investors. 17.7% of Soleno Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Soleno Therapeutics and Hyperfine’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Soleno Therapeutics N/A -142.17% -73.31%
Hyperfine N/A -60.78% -13.81%

Analyst Recommendations

This is a summary of current ratings and price targets for Soleno Therapeutics and Hyperfine, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Soleno Therapeutics 0 0 0 0 N/A
Hyperfine 0 0 1 0 3.00

Hyperfine has a consensus target price of $8.00, indicating a potential upside of 237.55%. Given Hyperfine’s higher probable upside, analysts plainly believe Hyperfine is more favorable than Soleno Therapeutics.

Earnings and Valuation

This table compares Soleno Therapeutics and Hyperfine’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Soleno Therapeutics N/A N/A -$30.91 million ($0.35) -0.48
Hyperfine $1.50 million 111.12 -$64.85 million N/A N/A

Soleno Therapeutics has higher earnings, but lower revenue than Hyperfine.

Summary

Hyperfine beats Soleno Therapeutics on 6 of the 9 factors compared between the two stocks.

About Soleno Therapeutics (Get Rating)

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

About Hyperfine (Get Rating)

Hyperfine, Inc. provides imaging, monitoring, and magnetic resonance imaging products. It offers Swoop Portable MR imaging system to address an unmet need in point-of-care medical imaging through a combination of hardware and software services. The company was incorporated in 2014 and is based in Guilford, Connecticut.

Receive News & Ratings for Soleno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soleno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.